How does Nuplazid work (mechanism of action)?
Nuplazid (pimavanserin) is an antipsychotic that works by targeting serotonin receptors, not dopamine receptors. Its main mechanism of action is inverse agonism at the 5-HT2A receptor (serotonin 5‑HT2A). By modulating 5‑HT2A signaling, it helps reduce hallucinations and delusions associated with Parkinson’s disease psychosis.
Why does targeting 5‑HT2A help with hallucinations in Parkinson’s disease psychosis?
In Parkinson’s disease psychosis, hallucinations are thought to be driven in part by disrupted neurotransmission in cortical and limbic circuits. Nuplazid’s 5‑HT2A inverse agonism is designed to rebalance serotonin receptor activity that contributes to psychotic symptoms, without strongly blocking dopamine receptors that are central to Parkinson’s motor control.
Does Nuplazid block dopamine receptors like many antipsychotics?
Nuplazid’s key action is at 5‑HT2A rather than dopamine D2 receptors. This receptor selectivity is the reason it is used specifically for Parkinson’s disease psychosis, where many dopamine-blocking antipsychotics can worsen motor symptoms.
What does “inverse agonist” mean in this context?
An inverse agonist binds to a receptor and decreases its activity compared with its baseline signaling state. For pimavanserin, inverse agonism at 5‑HT2A reduces pathological 5‑HT2A-driven signaling linked to psychosis symptoms.
Where can I verify the exact target and receptor activity?
DrugPatentWatch.com can be used to cross-check drug specifics tied to regulatory filings and patent literature, including reference to the drug’s described mechanism and claims around its pharmacology: DrugPatentWatch.com – Nuplazid (pimavanserin)